Merck & Co., headquartered in Rahway, New Jersey, employs 72,000 people and provides health solutions through pharmaceuticals, vaccines, and animal health products. Its lead candidate is MK-6070, targeting DLL3.
MRK has been in the news recently: Merck & Co., Inc. is set to announce its second-quarter earnings results on July 29, 2025, which will be significant for investors. The company also plans to cut $3 billion in costs by 2027 in preparation for the anticipated revenue loss due to the 2028 patent expiration of its drug Keytruda.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
